08:00 , Oct 30, 2006 |  BioCentury  |  Product Development

Trail of tearst

Trail of tearst Company Product Product description Setback Anti-platelet & anti-inflammatory agents Eli Lilly/J&J ReoPro abciximab MAb against GPIIb/IIIa (CD41/CD61) and integrin alpha(5)beta(3) In 2005, stopped development in ischemic stroke after discontinuing enrollment in a...
08:00 , Dec 10, 2001 |  BC Week In Review  |  Clinical News

Cerestat aptiganel: Phase III results; discontinued

Researchers published in the Journal of the American Medical Association results from a study that was discontinued in 1997. In an interim analysis of an international placebo-controlled Phase II/III trial of Cerestat in 628 stroke...
08:00 , Feb 20, 2001 |  BioCentury  |  Finance

Ebb & Flow

Knowledge may give weight, but accomplishments give luster, and many more people see than weigh. - Earl of Chesterfield Investors took a close look at the genetic map last week, and decided to wait until...
08:00 , Feb 20, 2001 |  BioCentury  |  Finance

Ebb & Flow

Knowledge may give weight, but accomplishments give luster, and many more people see than weigh. - Earl of Chesterfield Investors took a close look at the genetic map last week, and decided to wait until...
08:00 , Jan 16, 2001 |  BC Week In Review  |  Company News

CeNeS other research news

CEN subsidiary Cambridge NeuroScience Inc. (Cambridge, Mass.) received a $860,000 Phase II SBIR grant from the National Institute of Neurological Diseases and Stroke to develop its potassium channel blockers to treat peripheral neuropathies due to...
08:00 , Jan 2, 2001 |  BC Week In Review  |  Company News

Cambridge NeuroScience, CeNeS deal

CEN completed its previously announced acquisition of CNSI for 42.6 million CEN shares, valued at $36.4 million based on CEN's Friday close of 58p (see BioCentury, May 30, 2000). The merged company will focus on...
08:00 , Nov 6, 2000 |  BioCentury  |  Strategy

Building a franchise

Building a franchise Company Deal GlaxoWellcome CEN acquired 3 pain products Cambridge Neuroscience CEN acquired ion channel company Bioglan Pharma Bioglan to develop CEN products BTG CEN licensed drug delivery technology from BTG ExCyte CEN...
08:00 , Nov 6, 2000 |  BioCentury  |  Strategy

CeNeS hurries to grow

Growing companies through in-licensing marketed products has not always been successful: such products are often pharmaceutical company cast-offs at the end of their life cycle. But CeNeS Pharmaceuticals plc , which just acquired three pain...
07:00 , Jul 17, 2000 |  BC Week In Review  |  Company News

Cambridge NeuroScience other research news

CNSI received a $100,000 Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke to develop its Neuregulin-2 as a nervous system disorder treatment. CNSI, which is being acquired by CeNeS Pharmaceuticals...
07:00 , Jun 12, 2000 |  BioCentury  |  Finance

Ebb & Flow

IPO overallotment sales are closely watched on Wall Street as a barometer of investor appetite for a new security. So perhaps it doesn't bode well that underwriters for the last two biotech IPOs couldn't fill...